These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 29678273)
1. Preoperative CT-based predictive factors for resectability and medium-term overall survival in patients with peritoneal carcinomatosis from colorectal cancer. Suzuki C; Wallgren H; Abraham-Nordling M; Palmer G Clin Radiol; 2018 Aug; 73(8):756.e11-756.e16. PubMed ID: 29678273 [TBL] [Abstract][Full Text] [Related]
2. (18)F-FDG-PET/CT to select patients with peritoneal carcinomatosis for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Pfannenberg C; Königsrainer I; Aschoff P; Oksüz MO; Zieker D; Beckert S; Symons S; Nieselt K; Glatzle J; Weyhern CV; Brücher BL; Claussen CD; Königsrainer A Ann Surg Oncol; 2009 May; 16(5):1295-303. PubMed ID: 19252950 [TBL] [Abstract][Full Text] [Related]
3. Clinical Value of (18)F-FDG- PET-CT in the Preoperative Staging of Peritoneal Carcinomatosis from Colorectal Origin. De Vos N; Goethals I; Ceelen W Acta Chir Belg; 2014; 114(6):370-5. PubMed ID: 26021680 [TBL] [Abstract][Full Text] [Related]
4. Impact of aggressive histology and location of primary tumor on the efficacy of surgical therapy for peritoneal carcinomatosis of colorectal origin. Winer J; Zenati M; Ramalingam L; Jones H; Zureikat A; Holtzman M; Lee K; Ahrendt S; Pingpank J; Zeh HJ; Bartlett DL; Choudry HA Ann Surg Oncol; 2014 May; 21(5):1456-62. PubMed ID: 24201745 [TBL] [Abstract][Full Text] [Related]
5. Cytoreduction plus hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis in colorectal cancer patients: a single-center cohort study. Solaini L; D'Acapito F; Passardi A; Framarini M; Tauceri F; Di Pietrantonio D; Frassineti GL; Casadei Gardini A; Cucchetti A; Cavaliere D; Ercolani G World J Surg Oncol; 2019 Mar; 17(1):58. PubMed ID: 30917826 [TBL] [Abstract][Full Text] [Related]
6. Use of (18)F-FDG PET/CT in the preoperative evaluation of patients diagnosed with peritoneal carcinomatosis of ovarian origin, candidates to cytoreduction and hipec. A pending issue. Lopez-Lopez V; Cascales-Campos PA; Gil J; Frutos L; Andrade RJ; Fuster-Quiñonero M; Feliciangeli E; Gil E; Parrilla P Eur J Radiol; 2016 Oct; 85(10):1824-1828. PubMed ID: 27666623 [TBL] [Abstract][Full Text] [Related]
7. Preoperative computed tomography and selection of patients with colorectal peritoneal carcinomatosis for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. de Bree E; Koops W; Kröger R; van Ruth S; Verwaal VJ; Zoetmulder FA Eur J Surg Oncol; 2006 Feb; 32(1):65-71. PubMed ID: 16290055 [TBL] [Abstract][Full Text] [Related]
8. Postoperative complications affect long-term outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis. Lee L; Alie-Cusson F; Dubé P; Sideris L J Surg Oncol; 2017 Aug; 116(2):236-243. PubMed ID: 28409831 [TBL] [Abstract][Full Text] [Related]
9. Predictive factors of non-completion of cytoreductive surgery in colorectal peritoneal metastasis. Boldrin V; Khaled C; El Asmar A; Kamden L; Sclafani F; Gomez MG; Moreau M; Vouche M; Liberale G Eur J Surg Oncol; 2024 Feb; 50(2):107251. PubMed ID: 38096699 [TBL] [Abstract][Full Text] [Related]
10. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504 [TBL] [Abstract][Full Text] [Related]
11. Survival prognostic factors in patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy: a single institution experience. Nikolic S; Dzodic R; Zegarac M; Djurisic I; Gavrilovic D; Vojinovic V; Kocic M; Santrac N; Radlovic P; Radosavljevic D; Pupic G; Martinovic A J BUON; 2014; 19(1):66-74. PubMed ID: 24659645 [TBL] [Abstract][Full Text] [Related]
12. Predictive and prognostic survival factors in peritoneal carcinomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Jimenez W; Sardi A; Nieroda C; Sittig M; Milovanov V; Nunez M; Aydin N; Gushchin V Ann Surg Oncol; 2014 Dec; 21(13):4218-25. PubMed ID: 24986239 [TBL] [Abstract][Full Text] [Related]
13. Resectability of Peritoneal Carcinomatosis: Learnings from a Prospective Cohort of 533 Consecutive Patients Selected for Cytoreductive Surgery. Mohkam K; Passot G; Cotte E; Bakrin N; Gilly FN; Ledochowski S; Bernard L; Valette PJ; Glehen O; Rousset P Ann Surg Oncol; 2016 Apr; 23(4):1261-70. PubMed ID: 26628435 [TBL] [Abstract][Full Text] [Related]
14. The impact of radiological retroperitoneal lymphadenopathy on survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases. van der Werf LR; Wassenaar E; de Niet A; Lalezari F; Braam HJ; van Ramshorst B; Nederend J; de Hingh IHJT; Kok NFM; Aalbers AGJ Eur J Surg Oncol; 2019 Mar; 45(3):376-382. PubMed ID: 30414704 [TBL] [Abstract][Full Text] [Related]
15. Curative cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis and synchronous resectable liver metastases arising from colorectal cancer. Lorimier G; Linot B; Paillocher N; Dupoiron D; Verrièle V; Wernert R; Hamy A; Capitain O Eur J Surg Oncol; 2017 Jan; 43(1):150-158. PubMed ID: 27839895 [TBL] [Abstract][Full Text] [Related]
16. Peritoneal cancer patients not suitable for cytoreductive surgery and HIPEC during explorative surgery: risk factors, treatment options, and prognosis. van Oudheusden TR; Braam HJ; Luyer MD; Wiezer MJ; van Ramshorst B; Nienhuijs SW; de Hingh IH Ann Surg Oncol; 2015 Apr; 22(4):1236-42. PubMed ID: 25319584 [TBL] [Abstract][Full Text] [Related]
17. Assessment of relapse in patients with peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy using F-18-FDG-PET/CT. Klumpp B; Schwenzer NF; Gatidis S; Koenigsrainer I; Koenigsrainer A; Beckert S; Mueller M; Claussen CD; Pfannenberg C Rofo; 2014 Apr; 186(4):359-66. PubMed ID: 24683168 [TBL] [Abstract][Full Text] [Related]
18. Peritoneal carcinomatosis with synchronous liver metastases from colorectal cancer: Who will benefit from complete cytoreductive surgery? Delhorme JB; Dupont-Kazma L; Addeo P; Lefebvre F; Triki E; Romain B; Meyer N; Bachellier P; Rohr S; Brigand C Int J Surg; 2016 Jan; 25():98-105. PubMed ID: 26607853 [TBL] [Abstract][Full Text] [Related]
19. Accuracy of FDG-PET/CT in Colorectal Peritoneal Carcinomatosis: Potential Tool for Evaluation of Chemotherapeutic Response. Liberale G; Lecocq C; Garcia C; Muylle K; Covas A; Deleporte A; Hendlisz A; Bouazza F; El Nakadi I; Flamen P Anticancer Res; 2017 Feb; 37(2):929-934. PubMed ID: 28179354 [TBL] [Abstract][Full Text] [Related]
20. Predictors of Severe Morbidity After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Patients With Colorectal Peritoneal Carcinomatosis. Simkens GA; van Oudheusden TR; Luyer MD; Nienhuijs SW; Nieuwenhuijzen GA; Rutten HJ; de Hingh IH Ann Surg Oncol; 2016 Mar; 23(3):833-41. PubMed ID: 26442921 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]